Future of Cancer Care Today (FCCT)

There is more science available to cancer patients than what one care team can keep up with. New diagnostics, treatments, trials, and suppliers keep emerging, and when standard of care runs out, patients are usually left to figure out what else might be possible on their own.

Future of Cancer Care Today (FCCT) helps cancer patients and their families connect the dots. Our PhD-led team surfaces diagnostic and treatment options relevant to a patient's case, including those beyond standard of care, and finds vetted suppliers and providers who work beyond standard protocols. FCCT does not replace doctors or make treatment decisions. We create playbooks and curate resources to help families ask better questions, so they can walk into the next conversation with a fuller picture.

Future of Cancer Care Today is not a medical provider. We do not diagnose, prescribe, or direct treatment. We provide a non-clinical support layer focused on information, education, and decision support, intended to complement your relationship with your care team. Some materials may be generated with the support of artificial intelligence and should be reviewed with your medical providers before informing any care decisions. All decisions regarding your care belong to you and your doctor.

A curated body of suppliers, clinicians, and research groups we have encountered through our work.

Listings are informational only. FCCT does not endorse, certify, or control these suppliers, and inclusion does not imply a referral or recommendation. Please verify details directly with the supplier and discuss any next steps with the patient’s care team.

Services that preserve a patient's tumor tissue at biopsy or surgery for future testing, including therapies that may not yet exist at the time of collection.

StoreMyTumor (US, Europe). Patient-orderable.

Kernis Health (US). Patient-orderable. Even One Ventures company.

Tests that examine the molecular features of a tumor, including mutations, gene expression, proteins, and biomarkers, to help identify potential treatment targets. Usually performed on biopsy or surgical tissue.

Caris Life Sciences (US). Physician-ordered.

Foundation Medicine (US). Accepts international patients. Physician-ordered.

Boston Gene (US). Also includes immune microenvironment analysis. Accepts international patients. Physician-ordered.

Noetik (US). Whole-exome sequencing, spatial profiling, and IHC with raw data returned to the patient. Collaborate with patients.

Valius Sciences (US). Maximalist diagnostics adding single-cell and proteomic profiling. Patient-orderable. Even One Ventures company.

Protean BioDiagnostics (US). Comprehensive precision oncology testing with patient consultation. Patient accessible, physician-ordered.

Belay Diagnostics (US). CSF-based genomic profiling for brain and spinal cord tumors, useful when tissue biopsy is risky or unavailable. Physician-ordered.

CNSide Diagnostics (US). CSF circulating tumor cell capture with molecular profiling for leptomeningeal disease, often detecting cases that conventional cytology misses. Physician-ordered.

RGCC International (Worldwide). Blood-based circulating tumor cell molecular profiling for treatment guidance. Patient or physician-ordered.

Navignostics (Switzerland). Spatial single-cell proteomic tumor analysis from a single FFPE section. Physician-ordered through early-access partner program.

BC Cancer Personalized Oncogenomics Program (Canada). Referral pathway in Canada.

CeGaT (Germany). Tumor-normal comparison with patient-specific neoantigen identification. Physician-ordered.

Hartwig Medical Foundation (Netherlands). Referral through participating Dutch hospitals.

Vicinity Bio(Germany). Ultra-high-plex spatial proteomic tissue imaging with AI-driven pathology reports and biomarker-based therapy guidance. Physician-ordered.

Tests that grow a patient’s tumor cells or tumor models in the lab and expose them to cancer drugs to assess which treatments may show activity.

Travera (US). Live-cell screening including immunotherapies. Physician-ordered.

First Ascent Biomedical (US). Live-cell drug response across 150+ FDA-approved therapies. Physician-ordered.

Kiyatec(US). Ex vivo 3D drug response testing focused on ovarian, breast, glioblastoma, and rare tumors. Physician-ordered.

Cure-First (US). Nonprofit offering organoid generation and drug screening of 47+ anticancer agents drawn from a 200+ drug library. Patient-accessible.

SageMedic (US). Physician-ordered live-cell functional drug testing for solid tumors, including rare cancers and cancers of unknown primary, using 3D microtumors to assess tumor-cell killing, growth inhibition, and drug-combination activity.

KYAN Technologies (Singapore/US).Live-cell functional precision medicine using proprietary AI to evaluate and rank 1,500+ personalized drug combinations. Physician-ordered.

CanCertain (UK). 3D cell-culture drug testing on tumor cells from blood-based circulating tumor cells, compatible with immunotherapy testing. Patient or physician-ordered.

2cureX (Denmark). Through hospitals in Denmark, Germany, Sweden, and the UK. Physician-ordered.

Blood-based tests that detect tumor DNA or other cancer-related signals to monitor disease over time, including residual disease, recurrence, and treatment response.

Adaptive Biotechnologies (US). FDA-cleared MRD test, for B-cell malignancies (multiple myeloma, B-ALL, CLL, DLBCL). Physician-ordered.

BillionToOne (US). Tissue-free treatment monitoring and genomic profiling. Physician-ordered.

Caris Life Sciences (US). AI-enabled whole-exome and transcriptome blood assay. Physician-ordered.

Foundation Medicine (US). Tumor-informed ctDNA monitoring developed with Natera. Physician-ordered.

Guardant Health (US). Tissue-free MRD and therapy response monitoring. Physician-ordered.

Labcorp (US). Tumor-informed MRD across solid tumors, launched January 2026. Physician-ordered.

Natera (US). Tumor-informed personalized ctDNA assay for solid tumors. Physician-ordered.

NeoGenomics (US). Personalized MRD across solid tumors. Physician-ordered.

Personalis (US). Whole-genome tumor-informed MRD. Physician-ordered.

Quest Diagnostics (US). Tumor-informed ctDNA test with limit of detection at 0.0006%. Physician-ordered.

Tempus (US). MRD and recurrence monitoring, powered by Personalis NeXT Personal Dx via partnership. Physician-ordered.

Veracyte (US). Whole-genome MRD for muscle-invasive bladder cancer (coming in H1 2026; acquired from C2i Genomics). Physician-ordered.

Belay Diagnostics (US). CSF-based monitoring of primary and metastatic brain and spinal cord tumors, including detecting recurrence and distinguishing pseudoprogression from true progression. Physician-ordered.

CNSide Diagnostics (US). Longitudinal CSF monitoring of leptomeningeal disease through circulating tumor cell quantification and tracking of molecular markers. Physician-ordered.

RGCC International (Worldwide). Blood-based circulating tumor cell counts over time for monitoring disease activity and treatment response. Patient or physician-ordered.

Tests that characterize a patient’s immune system and its interaction with cancer, including immune-cell types, immune activity, and T-cell or B-cell patterns that may inform immunotherapy discussions.

Personalis (US). Combines tumor sequencing with neoantigen prediction, TCR repertoire, and immune cell composition. Physician-ordered.

Adaptive Biotechnologies (US). FDA-cleared minimal residual disease assay for B-cell malignancies (multiple myeloma, ALL, CLL, DLBCL). Physician-ordered.

Arden Bio (US). Adds biology-matched immune therapy recommendations alongside tumor microenvironment profiling. Patient-orderable. Even One Ventures company.

Pathfinder Oncology (US). Bespoke immune profiling and analysis as part of personalized treatment-pathway work for advanced cancer, led by William Hoos. Patient-accessible.

Navignostics (Switzerland). Spatial single-cell proteomic profiling of tumor-immune cell interactions from a single FFPE section. Physician-ordered through early-access partner program.

Imaging and treatment approaches that use tumor-associated markers to locate disease, validate targets, or deliver targeted radiation. Examples include PSMA in prostate cancer and somatostatin receptors in neuroendocrine tumors.

New York Proton Center (US). Proton-beam radiation therapy for solid tumors. Patient-bookable through oncology referral.

Excel Diagnostics and Nuclear Oncology Center (US). Patient-bookable through oncology referral.

Johns Hopkins Theranostics Center (US). Referral through oncology consult.

Relit (US). Consult services for finding custom radioligand imaging agents with biomarker-targeted design. Patient-orderable. Even One Ventures company.

Princess Margaret Cancer Centre Theranostics (Canada). Referral pathway in Canada.

Curanosticum Wiesbaden-Frankfurt (Germany). Led by Dr. Richard Baum, with FAPI PET and investigational radioligand therapies. Patient-bookable through oncology referral.

University Hospital Essen Nuclear Medicine (Germany). Patient-bookable through oncology referral.

Royal Marsden Theranostic Centre (UK). Referral pathway in UK.

Therapies that train the immune system to recognize and attack tumor-specific proteins. Most cancer vaccines today are only accessible through clinical trial enrollment. The exceptions are largely on the peptide side: a handful of clinics and programs can deliver personalized peptide vaccines to patients who do not qualify for trials, while personalized mRNA vaccines remain almost entirely confined to sponsor-run trials. Practically, this means a peptide vaccine is more obtainable today.

Jaime Leandro Foundation (US). Personalized peptide vaccines through FDA Expanded Access (compassionate use) when no trial is available. Patient-orderable.

Invoke Bio (US). Modality-agnostic neoantigen design (peptide, DNA, mRNA). Patient-orderable.

CeCurio (Germany). Personalized peptide vaccines through CeGaT collaboration, with real-world survival data in glioblastoma. Patient-bookable in Germany.

Northwest Biotherapeutics (US, UK). Personalized autologous dendritic cell vaccine for glioblastoma and other solid tumors in clinical trials.

Immunocine (Mexico). Personalized dendritic cell therapy at a Cancun clinic for patients with stage IV solid tumors who do not qualify for US trials. Patient-bookable, self-pay.

Diakonos Oncology (US). Patient-derived dendritic cell therapy with trials underway in glioblastoma, pancreatic and melanoma. Trial enrollment.

Elicio Therapeutics (US). Lymph-node-targeted peptide vaccine against common KRAS mutations, in Phase 2 for pancreatic cancer. Trial enrollment.

UbiVac (US). Off-the-shelf vaccine targeting proteins from non-coding genome regions, with RNAseq-based screening for target expression. Clinical-stage with good data in head and neck cancer. Trial enrollment.

Moderna (US). Personalized mRNA neoantigen vaccines. Trial enrollment.

Houston Methodist Center for RNA Therapeutics (US). Academic mRNA vaccine program led by Dr. John Cooke. Trial enrollment as studies open.

BioNTech (Germany). Personalized mRNA neoantigen vaccines. Trial enrollment.

IO Biotech (Denmark). Off-the-shelf peptide vaccine targeting IDO and PD-L1. Trial enrollment.

Echo (US). Personalized mRNA vaccines designed and manufactured for individual patients. Patient-orderable. Even One Ventures company.

Therapies that use engineered immune cells (CAR-T, TCR-T), tumor-infiltrating lymphocytes (TIL), or antibodies to target cancer. Most are accessed through clinical trial enrollment; FDA-approved exceptions noted below.

Iovance (US). First FDA-approved TIL therapy for advanced melanoma, with several others in trials. Available at authorized treatment centers in the US.

UCSF Cancer Immunotherapy Program (US). Standard-of-care CAR-T for B-cell blood cancers and multiple myeloma; trials in solid tumors. Referral throug